Adenosine inhibits collagen and total protein synthesis in vascular smooth muscle cells

被引:41
作者
Dubey, RK
Gillespie, DG
Jackson, EK
机构
[1] Univ Pittsburgh, Med Ctr, Ctr Clin Pharmacol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Med Ctr, Dept Pharmacol, Pittsburgh, PA 15213 USA
[4] Univ Zurich Hosp, Dept Obstet & Gynecol, CH-8091 Zurich, Switzerland
[5] Univ Zurich Hosp, Clin Endocrinol, CH-8091 Zurich, Switzerland
关键词
adenosine; muscle; smooth; extracellular matrix; collagen; hypertrophy;
D O I
10.1161/01.HYP.33.1.190
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The objective of this study was to characterize the effects of exogenous, drug-induced and cAMP-adenosine pathway-derived adenosine on collagen synthesis by and hypertrophy of vascular smooth muscle cells (SMCs). Confluent vascular SMCs were stimulated with 2.5% fetal calf serum in the presence and absence of adenosine receptor agonists [adenosine, 2-chloroadenosine, N-6-cyclopentyladenosine, 5'-N-ethylcarboxamidoadenosine, 5'-N-methylcarboxamidoadenosine, and 2-p-(2-carboxyethyl)phenethylamino-5'-N-adenosine], drugs that increase levels of endogenous adenosine [erythro-9-(2-hydroxy-3-nonyl) adenine, dipyridamole, and iodotubericidin], and cAMP (increases adenosine by conversion to AMP and hence to adenosine via the cAMP-adenosine pathway). Adenosine receptor agonists inhibited fetal calf serum-induced collagen and total protein synthesis las assessed by [H-3]proline and [H-3]leucine incorporation, respectively) with a relative potency profile consistent with the effects being mediated by adenosine A(2B) receptors. Erythro-9-(2-hydroxy-3-nonyl) adenine, dipyridamole, iodotubericidin, and cAMP also inhibited collagen and total protein synthesis. The effects of 2-chloroadenosine, erythro-9-(2-hydroxy-3-nonyl) adenine, iodotubericidin, and cAMP on collagen and total protein synthesis were attenuated by KF17837 and 1,3-dipropyl-8-p-sulfophenylxanthine (selective and nonselective A, receptor antagonists, respectively) but not by 8-cyclopentyl-1,3-dipropylxanthine (selective A(1) receptor antagonist). These studies indicate that exogenous, drug-induced and cAMP-adenosine pathway-derived adenosine inhibit vascular SMC collagen synthesis and hypertrophy via A(2B) receptors, Thus, exogenous A(2B) receptor agonists and drugs that modulate endogenous adenosine levels may protect against vasoocclusive disorders by attenuating extracellular matrix synthesis by and cellular hypertrophy of vascular SMCs. Moreover, the cAMP-adenosine pathway may protect against vascular hypertrophy.
引用
收藏
页码:190 / 194
页数:5
相关论文
共 9 条
  • [1] DALZIEL HH, 1994, PHARMACOL REV, V46, P449
  • [2] Adenosine inhibits growth of rat aortic smooth muscle cells - Possible role of A(2b) receptor
    Dubey, RK
    Gillespie, DG
    Osaka, K
    Suzuki, F
    Jackson, EK
    [J]. HYPERTENSION, 1996, 27 (03) : 786 - 793
  • [3] Smooth muscle cell-derived adenosine inhibits cell growth
    Dubey, RK
    Gillespie, DG
    Mi, ZC
    Suzuki, F
    Jackson, EK
    [J]. HYPERTENSION, 1996, 27 (03) : 766 - 773
  • [4] Cyclic AMP adenosine pathway induces nitric oxide synthesis in aortic smooth muscle cells
    Dubey, RK
    Gillespie, DG
    Jackson, EK
    [J]. HYPERTENSION, 1998, 31 (01) : 296 - 302
  • [5] Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors
    Dubey, RK
    Gillespie, DG
    Mi, ZC
    Jackson, EK
    [J]. HYPERTENSION, 1998, 31 (01) : 516 - 521
  • [6] Cyclic AMP Adenosine pathway inhibits vascular smooth muscle cell growth
    Dubey, RK
    Mi, ZC
    Gillespie, DG
    Jackson, EK
    [J]. HYPERTENSION, 1996, 28 (05) : 765 - 771
  • [7] Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts - Role of A(2B) receptors
    Dubey, RK
    Gillespie, DG
    Mi, ZC
    Jackson, EK
    [J]. CIRCULATION, 1997, 96 (08) : 2656 - 2666
  • [8] FUNCTIONAL-CHARACTERIZATION OF 3 ADENOSINE RECEPTOR TYPES
    GURDEN, MF
    COATES, J
    ELLIS, F
    EVANS, B
    FOSTER, M
    HORNBY, E
    KENNEDY, I
    MARTIN, DP
    STRONG, P
    VARDEY, CJ
    WHEELDON, A
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 (03) : 693 - 698
  • [9] Jackson EK, 1996, J HYPERTENS, V14, P19